← Back to patent-cliff list
CAS 80-57-9
4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one
Codes：(I)101438-31-a
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one→1-Bromo-3-methyl-2-butene→2-{2,6,6-trimethyl-4-oxobicyclo[3.1.1]hept-2-en-3-yl}acetaldehyde→2-{2,6,6-trimethyl-7-oxobicyclo[3.1.1]hept-2-en-1-yl}acetaldehyde→ethyl (2S,6R)-2,6-dihydroxy-4,10,11,11-tetramethyl-3-oxotricyclo[5.3.1.0(1,6)]undeca-4,9-diene-5-carboxylate→(Ethoxycarbonyl)acetylene→ethyl 5-{2,6,6-trimethyl-7-oxobicyclo[3.1.1]hept-2-en-1-yl}-4-[(trimethylsilyl)oxy]pent-2-ynoate→ethyl (6R)-3,6-dihydroxy-4,10,11,11-tetramethyltricyclo[5.3.1.0(1,6)]undeca-4,9-diene-5-carboxylate→ethyl (6R)-6-hydroxy-4,10,11,11-tetramethyl-3-oxotricyclo[5.3.1.0(1,6)]undeca-4,9-diene-5-carboxylate→(2S,3S,6S)-5-(hydroxymethyl)-4,10,11,11-tetramethyltricyclo[5.3.1.0(1,6)]undeca-4,9-diene-2,3,6-triol→(2S,6S,9S)-8-{[(tert-butyldimethylsilyl)oxy]methyl}-4,4,7,13,14,14-hexamethyl-3,5-dioxatetracyclo[8.3.1.0(1,9).0(2,6)]tetradeca-7,12-dien-9-ol→(2S,6S,7Z,12S)-8-{[(tert-butyldimethylsilyl)oxy]methyl}-4,4,7,13,14,14-hexamethyl-12-{[tris(propan-2-yl)silyl]oxy}-3,5-dioxatricyclo[8.3.1.0(2,6)]tetradeca-1(13),7-dien-9-one→(2S,6S,7Z,9S,10S,12S)-8-(hydroxymethyl)-4,4,7,13,14,14-hexamethyl-12-[(triisopropylsilyl)oxy]-3,5-dioxatricyclo[8.3.1.0(2,6)]tetradeca-1(13),7-diene-9,10-diol→(1S,5S,6S,7S,8S,12S,15S)-7,10,10,14,17,17-hexamethyl-6-{[(trimethylsilyl)oxy]methyl}-15-{[tris(propan-2-yl)silyl]oxy}-2,4,9,11-tetraoxatetracyclo[11.3.1.0(1,5).0(8,12)]heptadec-13-en-3-one→(1S,5S,6R,7S,8S,12S,15S)-7,10,10,14,17,17-hexamethyl-3-oxo-15-[(triisopropylsilyl)oxy]-2,4,9,11-tetraoxatetracyclo[11.3.1.0(1,5).0(8,12)]heptadec-13-ene-6-carbaldehyde→2-[(1S,5S,6R,7S,8S,9S,12S)-8,9-dihydroxy-7,11,14,14-tetramethyl-3-oxo-12-{[tris(propan-2-yl)silyl]oxy}-2,4-dioxatricyclo[8.3.1.0(1,5)]tetradec-10-en-6-yl]acetaldehyde→2-[(1S,5S,6S,7S,8S,12S)-7,11,14,14-tetramethyl-3,9-dioxo-8-[(triethylsilyl)oxy]-12-[(triisopropylsilyl)oxy]-2,4-dioxatricyclo[8.3.1.0(1,5)]tetradec-10-en-6-yl]prop-2-enal
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.